Natriuretic peptides A
Definition:
References:
-
[1]. M G Buckley, et al. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). Clin Sci (Lond). 1994 Sep;87(3):311-7. [Content Brief]
[2]. W Lenz, et al. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. Kidney Int. 1999 Jan;55(1):91-9. [Content Brief]
[3]. J P Valentin, et al. Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. Hypertension. 1993 Apr;21(4):432-8. [Content Brief]
[4]. Andreas L Birkenfeld, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2008 Dec;57(12):3199-204. [Content Brief]
[5]. D L Vesely, et al. Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126. Peptides. 1990 Mar-Apr;11(2):193-7. [Content Brief]
[6]. C Drummer, et al. Development and application of a urodilatin (CDD/ANP-95-126)-specific radioimmunoassay. Pflugers Arch. 1993 Jun;423(5-6):372-7. [Content Brief]
[7]. M L Weir, et al. Lack of biologic activity or specific binding of amino-terminal pro-ANP segments in the rat. Regul Pept. 1994 Sep 22;53(2):111-22. [Content Brief]
[8]. Luis A Ralat, et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011 Feb 11;286(6):4670-9. [Content Brief]
[9]. K J Koller, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science. 1991 Apr 5;252(5002):120-3. [Content Brief]
[10]. S Chiou, et al. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides. Endocrinology. 1995 May;136(5):2033-9. [Content Brief]
[11]. D L Vesely, et al. Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta. Biochem Biophys Res Commun. 1987 Nov 13;148(3):1540-8. [Content Brief]
[12]. R B Sothern, et al. Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol Int. 1995 Apr;12(2):106-20. [Content Brief]
[13]. Andreas L Birkenfeld, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab. 2005 Jun;90(6):3622-8. [Content Brief]
[14]. C Drummer, et al. Postprandial natriuresis in humans: further evidence that urodilatin, not ANP, modulates sodium excretion. Am J Physiol. 1996 Feb;270(2 Pt 2):F301-10. [Content Brief]
[15]. M Meyer, et al. Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects. Am J Physiol. 1996 Sep;271(3 Pt 2):F489-97. [Content Brief]
[16]. D L Vesely, et al. Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J Endocrinol. 1995 Sep;146(3):373-80. [Content Brief]
[17]. Speranza Rubattu, et al. The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells. PLoS One. 2014 Nov 17;9(11):e113108. [Content Brief]
[18]. D L Vesely, et al. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance the urinary excretion rate of beta2-microglobulin. Metabolism. 2000 Dec;49(12):1592-7. [Content Brief]
[19]. Marica Bordicchia, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012 Mar;122(3):1022-36. [Content Brief]
[20]. Sandra C Souza, et al. Atrial natriuretic peptide regulates lipid mobilization and oxygen consumption in human adipocytes by activating AMPK. Biochem Biophys Res Commun. 2011 Jul 8;410(3):398-403. [Content Brief]
[21]. T Dörner, et al. Phosphorylation and dephosphorylation of the natriuretic peptide urodilatin (CDD-/ANP-95-126) and the effect on biological activity. Biochem Biophys Res Commun. 1989 Sep 15;163(2):830-5. [Content Brief]
[22]. D L Vesely, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994 Sep;90(3):1129-40. [Content Brief]
[23]. Speranza Rubattu, et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006 Aug 1;48(3):499-505. [Content Brief]
[24]. D L Vesely, et al. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med. 1989 Dec;192(3):230-5. [Content Brief]
[25]. B D Bennett, et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem. 1991 Dec 5;266(34):23060-7. [Content Brief]